T he evaluation of patients presenting with stable but suspected coronary artery disease (CAD) is by far one of the most common diagnostic evaluation strategies undertaken within cardiovascular medicine. The 2 most prominent indications for testing supported by substantive clinical evidence include diagnosis of obstructive CAD and risk stratification. The evidence supporting prognostication based on diagnostic test findings in the patient with stable ischemic heart disease is abundant, with thousands of reports noting near-term prediction of major adverse events for all noninvasive procedures including anatomic imaging, with coronary computed tomographic angiography (CTA), and stress testing (ie, stress nuclear or echocardiography or exercise electrocardiography). Observational evidence for each modality supports that, in general, risk increases in a graded manner with the extent and severity of abnormalities on functional stress testing or with anatomic CAD.
This proportional relationship between the extent and severity of abnormalities and risk is the basis for therapeutic intervention whereby hazard drives the intensity of comprehensive management. 1 Conceptually, those with the most severe functional test abnormalities or those with obstructive CAD generally receive symptomguided anti-ischemic therapy and aggressive risk factor modification. Conversely, low-risk patients have few major CAD events and less prevalent CAD, and thereby should rarely warrant angiography to identify ischemia-associated lesions. But, if present, modifiable risk factors would normally still be addressed. This is the accepted standard approach to apply risk estimates into clinical management of patients with stable ischemic heart disease. There may, however, be profound differences, as perceived by the patient or the physician, in the need for therapy targeting modifiable risk factors when either functional or anatomic tests yield normal or intermediate results.
In this issue of Circulation, Hoffmann and colleagues report on the effectiveness of risk stratification using site-reported interpretation from the PROMISE trial (Prospective Multicenter Imaging Study for Evaluation of Chest Pain). 2 The use of site interpretations is in keeping with the pragmatic (or real-world) nature of this trial; however, the lack of integration of accepted standards into daily laboratory practice is a noteworthy limitation to the current findings. Prior evidence supports that site interpretations overestimate the severity of ischemia and likely contribute to frequent documentation of nonobstructive CAD on diagnostic coronary angiography. [3] [4] [5] The overcalling of test abnormalities is also the result of integrating the patient's symptoms and risk factor burden into the final interpretation, but also is purposely overly sensitive to avoid missing patients with underlying CAD. The authors also demonstrate again that, in the current era, traditional pretest probabilities that justify proceeding to any diagnostic strategy, particularly in the context of atypical chest pain that predominates in this study, may be too liberal, because the yield of positive test results that explain ischemic symptoms is <15%.
Findings from the PROMISE trial reveal that the relationship between increasing gradations of abnormality and risk are present for both CTA and stress testing. In fact, at the high end of the risk strata, documentation of moderate or severe ischemia, or at least single-vessel and anatomically significant CAD reveal similar event rates (≈2-year event rates: 9.2% versus 8.2%, P=0.58), similar discriminative power based on C-statistic assessment and comparable hazard ratios in comparison with test results regarded as either normal or mildly abnormal (3.47 versus 3.74 for functional versus anatomic testing). These findings are crucial to guiding posttest management, because intense care for the higher-risk patient subgroups would be warranted based on our current stable ischemic heart disease strategies of care. When considering low rates of newly initiated cardiovascular medications 6 and downstream invasive coronary angiography 7 and minimal changes in angina status over time, 7 as previously reported from the PROMISE trial, an opportunity exists to improve adherence to guidelinedirected management in an effort to perhaps further reduce risk among those with moderate or severe abnormalities on the index diagnostic procedure. Among those with normal or mildly abnormal test results, event rates were low but not eliminated (≈1%-2% during ≈2 years of follow-up). Whether intensive lifestyle and risk factor interventions in the lower-risk groups are warranted remains a source of debate.
Perhaps the most provocative finding from this analysis is that risk stratification with stress testing was not associated with a statistically significant increased hazard for events for those with mildly abnormal findings in comparison with completely normal results. This finding stands in contrast to that from expert centers whereby an intermediate risk of events is documented among those with mild ischemia. 8 One cannot exclude that this may be attributable to site reads that may lack the quality control required to identify this intermediate-risk subgroup. However, there may be more important reasons for the lack of risk stratification based on consideration of the relationship between ischemia and graded stenosis. 9 Event rates following a normal stress myocardial perfusion study are twice those of patients with normal coronary arteries on CTA. 10 Also, more than half of patients with normal stress myocardial perfusion findings have detectable coronary artery calcification, with as many as ≈1 in 5 having high-risk scores ≥400.
11 The increasing application of CTA has further revealed that the burden of luminal narrowing is far greater than is documented by ischemia on stress imaging, because not all stenosis will cause ischemia, particularly mild but also more severe luminal narrowing, as well. 12 This residual burden of undocumented and potentially nonischemiaproducing CAD was noted in the PROMISE trial because intermediate stenoses were frequently documented with nearly half of events occurring among this patient subgroup. These anatomic findings probably explain the lack of increment in risk between normal and mildly abnormal stress test findings. This unrecognized disease, even when not mediating ischemia at the time of testing, remains a powerful precursor and substrate of future events. Clearly, further research is warranted to define the relationship between ischemia, events, and underlying atherosclerosis, including high-risk plaque features. These findings support that delineation of normal coronary arteries versus minimally or mildly obstructive CAD is ineffective based on stress testing. These data suggest that alternative testing strategies of CTA first, followed by selective stress testing, should be evaluated because documentation of more than physiological data provides insight into future CAD event risk.
The PROMISE trial findings reveal important information about real-world test interpretation that is likely quite variable and inconsistent with standardized test interpretation. But, it is reassuring that these data look as good as they do, given the likely diverse approaches to test interpretation and the divergence from standardized, segmental scoring methods supported by imaging society guidelines. A review of prognostic findings by test modality supports variable risk stratification, and further inclusion of data among challenging patient cohorts would have enhanced the quality of the presented findings. In fact, we have very few data provided in this report on the adequacy of exercise, heart rate, blood pressure, symptomatic, or other test findings that are well-established prognosticators (eg, left ventricular ejection fraction). Across the investigator-derived categories of risk, the grouping of scarred with ischemic (ie, mixed) abnormalities may have muddied risk stratification in the functional test arm. These and other potential questions linger when reviewing the current article but perhaps will be revealed in future published reports.
Thus, this prespecified post hoc analysis from PROM-ISE indicates that, at the extremes, functional and anatomic testing as initial diagnostic strategies convey similar prognostic information. Using finer gradations of test results, prognostication is more precise and progressively incremental with the anatomic approach, largely by its ability to reliably detect the presence of atherosclerosis that is not anatomically moderate/severe and that is also not likely to be causing ischemia. The authors show that even this difference in prognostication is mollified when functional testing results are considered in concert with traditional risk factors, as reflected by the analyses that included the Framingham Risk Score. Thus, the implications of this augmented precision in risk stratification is immaterial with respect to antianginal and revascularization options, but of direct importance with respect to overcoming both physician and patient inertia to address or not address modifiable risk factors when present (see Table) . The safety and advisability of the latter, often focused mainly on withholding of statins, in the absence of the inability of either strategy to guarantee an event-free course, remains controversial. It is imperative, therefore, to maintain a very strong focus on appropriate risk factor assessment and modification in patients with or without chest pain, followed by judicious evaluation of results of either functional or anatomic testing when chest pain syndromes also require evaluation.
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